LBF20207PG23: Difference between revisions

No edit summary
No edit summary
Line 9: Line 9:
|Common Name=&&Prostaglandin E_2&&7- [ 3 (R) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl-5-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
|Common Name=&&Prostaglandin E_2&&7- [ 3 (R) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl-5-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
|Melting Point=65-66°C [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Melting Point=65-66°C [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Reflactive=[<FONT FACE="Symbol">a</FONT>]X<sub>D</sub><sup>26</sup>=-61.0°(C=1.0, TETRAHYDROFURAN) [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Optical=[<FONT FACE="Symbol">a</FONT>]X<sub>D</sub><sup>26</sup>=-61.0°(C=1.0, TETRAHYDROFURAN) [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Solubility= ETHYL ACETATE,THF,CHLOROFORM[[Reference:Donaldson_RE:Saddler_JC:Byrn_S:McKenzie_AT:Fuchs_PL:,J. Org. Chem.,1983,48,2167|{{RelationTable/GetFirstAuthor|Reference:Donaldson_RE:Saddler_JC:Byrn_S:McKenzie_AT:Fuchs_PL:,J. Org. Chem.,1983,48,2167}}]][[Reference:Sih_CJ:Heather_JB:Sood_R:Price_P:Peruzzotti_G:Lee_LF:Lee_SS:,J. Am. Chem. Soc.,1975,97,865|{{RelationTable/GetFirstAuthor|Reference:Sih_CJ:Heather_JB:Sood_R:Price_P:Peruzzotti_G:Lee_LF:Lee_SS:,J. Am. Chem. Soc.,1975,97,865}}]]. STABILITIES: to be stable under neutral condition. to decompose to PGA2 under acidic and to PGB2 under basic conditions [[Reference:Karim_SM:Devlin_J:Hillier_K:,Eur. J. Pharmacol.,1968,4,416|{{RelationTable/GetFirstAuthor|Reference:Karim_SM:Devlin_J:Hillier_K:,Eur. J. Pharmacol.,1968,4,416}}]][[Reference:Pike_J_E:Lincoln_FH:Schneider_WP:,J. Org. Chem.,1969,34,3552|{{RelationTable/GetFirstAuthor|Reference:Pike_J_E:Lincoln_FH:Schneider_WP:,J. Org. Chem.,1969,34,3552}}]]
|Solubility= ETHYL ACETATE,THF,CHLOROFORM[[Reference:Donaldson_RE:Saddler_JC:Byrn_S:McKenzie_AT:Fuchs_PL:,J. Org. Chem.,1983,48,2167|{{RelationTable/GetFirstAuthor|Reference:Donaldson_RE:Saddler_JC:Byrn_S:McKenzie_AT:Fuchs_PL:,J. Org. Chem.,1983,48,2167}}]][[Reference:Sih_CJ:Heather_JB:Sood_R:Price_P:Peruzzotti_G:Lee_LF:Lee_SS:,J. Am. Chem. Soc.,1975,97,865|{{RelationTable/GetFirstAuthor|Reference:Sih_CJ:Heather_JB:Sood_R:Price_P:Peruzzotti_G:Lee_LF:Lee_SS:,J. Am. Chem. Soc.,1975,97,865}}]]. STABILITIES: to be stable under neutral condition. to decompose to PGA2 under acidic and to PGB2 under basic conditions [[Reference:Karim_SM:Devlin_J:Hillier_K:,Eur. J. Pharmacol.,1968,4,416|{{RelationTable/GetFirstAuthor|Reference:Karim_SM:Devlin_J:Hillier_K:,Eur. J. Pharmacol.,1968,4,416}}]][[Reference:Pike_J_E:Lincoln_FH:Schneider_WP:,J. Org. Chem.,1969,34,3552|{{RelationTable/GetFirstAuthor|Reference:Pike_J_E:Lincoln_FH:Schneider_WP:,J. Org. Chem.,1969,34,3552}}]]
|Mass Spectra=d,l-mixture ; 334(M<SUP><FONT SIZE=-1>+</FONT></SUP>-18), 316, 298, 190 [[Reference:Chen_SML:Schaub_RE:Grudzinskas_CV:,J. Org. Chem.,1978,43,3450|{{RelationTable/GetFirstAuthor|Reference:Chen_SML:Schaub_RE:Grudzinskas_CV:,J. Org. Chem.,1978,43,3450}}]]
|Mass Spectra=d,l-mixture ; 334(M<SUP><FONT SIZE=-1>+</FONT></SUP>-18), 316, 298, 190 [[Reference:Chen_SML:Schaub_RE:Grudzinskas_CV:,J. Org. Chem.,1978,43,3450|{{RelationTable/GetFirstAuthor|Reference:Chen_SML:Schaub_RE:Grudzinskas_CV:,J. Org. Chem.,1978,43,3450}}]]
Line 17: Line 17:
|Chemical Synthesis={{Image200|LBF20207PG23FT0001.gif}} [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Chemical Synthesis={{Image200|LBF20207PG23FT0001.gif}} [[Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397|{{RelationTable/GetFirstAuthor|Reference:Corey_EJ:Schaaf_TK:Huber_W:Koelliker_U:Weinshenker_NM:,J. Am. Chem. Soc.,1970,92,397}}]]
|Metabolism=Prostaglandin E2 is produced from arachidonic acid via prostaglandins G2 and H2 by the catalyses of prostaglandin endoperoxide synthase (cyclooxygenase) [[Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157|{{RelationTable/GetFirstAuthor|Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157}}]] and prostaglandin E synthase [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257|{{RelationTable/GetFirstAuthor|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. Two isoforms of the cyclooxygnease enzyme responsible for prostaglandin H2 synthesis are present. Cyclooxygenase-1 is constitutively found in most mammalian tissues, while cyclooxygnease-2 is induced rapidly and transiently in physiological and pathological events, especially in inflammation [[Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157|{{RelationTable/GetFirstAuthor|Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157}}]]. The biological activities of prostaglandin E2 are lost by oxidation of its 15-hydroxyl group catalyzed by 15-hydroxyprostaglandin dehydrogenase [[Reference:Hansen_HS:,Prostaglandins,1976,12,647|{{RelationTable/GetFirstAuthor|Reference:Hansen_HS:,Prostaglandins,1976,12,647}}]].
|Metabolism=Prostaglandin E2 is produced from arachidonic acid via prostaglandins G2 and H2 by the catalyses of prostaglandin endoperoxide synthase (cyclooxygenase) [[Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157|{{RelationTable/GetFirstAuthor|Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157}}]] and prostaglandin E synthase [[Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257|{{RelationTable/GetFirstAuthor|Reference:Urade_Y:Watanabe_K:Hayaishi_O:,J. Lipid Mediat. Cell Signal.,1995,12,257}}]]. Two isoforms of the cyclooxygnease enzyme responsible for prostaglandin H2 synthesis are present. Cyclooxygenase-1 is constitutively found in most mammalian tissues, while cyclooxygnease-2 is induced rapidly and transiently in physiological and pathological events, especially in inflammation [[Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157|{{RelationTable/GetFirstAuthor|Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157}}]]. The biological activities of prostaglandin E2 are lost by oxidation of its 15-hydroxyl group catalyzed by 15-hydroxyprostaglandin dehydrogenase [[Reference:Hansen_HS:,Prostaglandins,1976,12,647|{{RelationTable/GetFirstAuthor|Reference:Hansen_HS:,Prostaglandins,1976,12,647}}]].
|Symbol=PGE2
|Biological Activity=Prostaglandin E2 exhibits various biological activities such as vasodilatation, uterine contraction, gastrointestinal contraction, bronchodilatation, diuresis, pyrexia, inhibition of gastric secretion, bone resorption and immunosuppression [[Reference:Bergstrom_S:Carlson_LA:Weeks_JR:,Pharmacol. Rev.,1968,20,1|{{RelationTable/GetFirstAuthor|Reference:Bergstrom_S:Carlson_LA:Weeks_JR:,Pharmacol. Rev.,1968,20,1}}]]. Prostaglandin E2 is a ligand to receptors present in the cell membrane, and there are at least 4 subtypes of its receptor. Different tissue distributions and signal transductions of these receptor subtypes explain a variety of biological activities of prostaglandin E2 [[Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109|{{RelationTable/GetFirstAuthor|Reference:Negishi_M:Sugimoto_Y:Ichikawa_A:,Biochim. Biophys. Acta,1995,1259,109}}]].
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Revision as of 21:00, 6 January 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



Prostaglandin E2
LBF20207PG23.png
Structural Information
7- [ 3 (R) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl-5-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid
  • Prostaglandin E2
  • 7- [ 3 (R) -Hydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl-5-oxocyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid
PGE2
Formula C20H32O5
Exact Mass 352.224974134
Average Mass 352.46508
SMILES C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](CC1=O)O)CC
Physicochemical Information
65-66°C Corey_EJ et al.
[a]XD26=-61.0°(C=1.0, TETRAHYDROFURAN) Corey_EJ et al.
ETHYL ACETATE,THF,CHLOROFORM Donaldson_RE et al. Sih_CJ et al.. STABILITIES: to be stable under neutral condition. to decompose to PGA2 under acidic and to PGB2 under basic conditions Karim_SM et al. Pike_JEet al.
Prostaglandin E2 was found to be accummulating in human semen in an amount of about 13 microgram per ml Bergstrom_S . In most animal tissues prostanoids are synthesized enzymatically de novo upon physiological and pathological stimulations, and this is also the case of prostaglandin E2.

LBF20207PG23FT0001.gif
Corey_EJ et al.
Prostaglandin E2 is produced from arachidonic acid via prostaglandins G2 and H2 by the catalyses of prostaglandin endoperoxide synthase (cyclooxygenase) Smith_WL et al. and prostaglandin E synthase Urade_Y et al.. Two isoforms of the cyclooxygnease enzyme responsible for prostaglandin H2 synthesis are present. Cyclooxygenase-1 is constitutively found in most mammalian tissues, while cyclooxygnease-2 is induced rapidly and transiently in physiological and pathological events, especially in inflammation Smith_WL et al.. The biological activities of prostaglandin E2 are lost by oxidation of its 15-hydroxyl group catalyzed by 15-hydroxyprostaglandin dehydrogenase Hansen_HS .
Prostaglandin E2 exhibits various biological activities such as vasodilatation, uterine contraction, gastrointestinal contraction, bronchodilatation, diuresis, pyrexia, inhibition of gastric secretion, bone resorption and immunosuppression Bergstrom_S et al.. Prostaglandin E2 is a ligand to receptors present in the cell membrane, and there are at least 4 subtypes of its receptor. Different tissue distributions and signal transductions of these receptor subtypes explain a variety of biological activities of prostaglandin E2 Negishi_M et al..
Spectral Information
Mass Spectra d,l-mixture ; 334(M+-18), 316, 298, 190 Chen_SML et al.
UV Spectra
IR Spectra d,l-mixture ; 3400, 1710, 970cm-1 Chen_SML et al.
NMR Spectra 13C-NMR(CDCl3) : 214.71(C9),178.39(C1), 136.62(C14), 131.52(C13), 130.91(C5), 126.69(C6), 73.19(C15), 72.13(C11), 54.55(C12), 53.51(C8), 46.23(C10), 37.00 (C16), 33.56(C2), 31.73(C18), 26.47(C4), 25.20(C7,17), 24.60(C3), 22.64(C19), 14.04. Donaldson_RE et al.. 1H-NMR(CDCl3) : d5.67(dd, J=6.6Hz, 15.4, 1H, 14-CH), 5.57(dd, J=8.1, 15.4Hz, 1H, 13-CH), 5.40(m, 2H, 5.6-CH), 4.12(q, J=6.5, 6.7, 6.8Hz, 1H, 15-CH), 4.06(q, J=8.1, 8.2, 8.3Hz, 1H, 11-CH), 2.72(dd, J= Donaldson_RE et al.
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20207PG23 See above. Bergstrom_S 1967
n.a. LBF20207PG23 See above. Bergstrom_S et al. 1968
n.a. LBF20207PG23 See above. Chen_SML et al. 1978
n.a. LBF20207PG23 See above. Corey_EJ et al. 1970
n.a. LBF20207PG23 See above. Donaldson_RE et al. 1983
n.a. LBF20207PG23 See above. Funk_CD 1993
n.a. LBF20207PG23 See above. Hansen_HS 1976
n.a. LBF20207PG23 See above. Herschman_HR 1996
n.a. LBF20207PG23 See above. Karim_SM et al. 1968
n.a. LBF20207PG23 See above. Negishi_M et al. 1995
n.a. LBF20207PG23 See above. Pike_JE et al. 1969
n.a. LBF20207PG23 See above. Sih_CJ et al. 1975
n.a. LBF20207PG23 See above. Smith_WL et al. 1996
n.a. LBF20207PG23 See above. Urade_Y et al. 1995